Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sustained-release morphine for refractory breathlessness in opioid-naive patients with mesothelioma, asbestosis, or interstitial lung disease
ACTRN12611000711910Phase 3Terminated
- Sponsor
- Flinders University
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of morphine in mesothelioma, asbestosis and interstitial lung disease (ILD) (2 arms), sponsored by Flinders University. Primary endpoint: Relief of breathlessness. Started Mar 2011; status: terminated.
02
Drugs
morphine
03
Conditions
mesotheliomaasbestosisinterstitial lung disease (ILD)
Beyond the preview
Go deeper on ACTRN12611000711910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000711910.